10 արդյունքներ
FIELD AND BACKGROUND OF THE INVENTION
The present invention, in some embodiments thereof, relates to adherent cells from placenta and use of same in disease treatment.
In recent years, considerable activity has focused on the therapeutic potential of mesenchymal stromal cells (MSCs) for various
FIELD AND BACKGROUND OF THE INVENTION
The present invention, in some embodiments thereof, relates to adherent cells from placenta and use of same in disease treatment.
In recent years, considerable activity has focused on the therapeutic potential of mesenchymal stromal cells (MSCs) for various
FIELD OF THE INVENTION
The present invention relates to methods for improving cell therapy in a patient. More specifically, the present invention relates to methods for improving cell therapy in patient who is suffering from a cardiovascular or a neurological disease by using shock waves as a
BACKGROUND OF THE INVENTION
This invention relates to compounds that inhibit the activity of protein kinases. Protein kinases are enzymes that catalyze the transfer of a phosphate group from ATP to an amino acid residue, such as tyrosine, serine, threonine, or histidine on a protein. Regulation of
FIELD OF THE INVENTION
The present invention relates to a pharmaceutical composition for treatment and/or prevention of a disease due to constriction or vasodilation of blood vessels comprising EDG(Endothelial differentiation gene)-5 modulator which is useful as a drug, and relates to novel EDG-5
The present invention relates to 2-aminothiophene derivatives, pharmaceutical compositions containing them, and to methods of treating conditions mediated by the A.sub.1 adenosine receptor including pain, in particular, chronic pain such as neuropathic pain, cardiac disease or disorder such as
The present invention relates to 2-aminothiophene derivatives, pharmaceutical compositions containing them, and to methods of treating conditions mediated by the A.sub.1 adenosine receptor including pain, in particular, chronic pain such as neuropathic pain, cardiac disease or disorder such as
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase of International Application No. PCT/US2014/027450 filed on Mar. 14, 2014, which claims the benefit of U.S. Provisional Application No. 61/785,478 filed on Mar. 14, 2013, each of which are incorporated herein by reference
BACKGROUND OF THE INVENTION
This invention relates to benzimidazolone derivatives. These compounds have selective cannabinoid(CB)2 receptor binding activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the
BACKGROUND OF THE INVENTION
This invention relates to sulfonyl benzimidazole derivatives. These compounds have selective cannabinoid (CB)2 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives